This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garcia-Calvo, G.
Right arrow Articles by Soriano, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garcia-Calvo, G.
Right arrow Articles by Soriano, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2001, p. 608-611, Vol. 45, No. 2
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.2.608-611.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Effects of Single Oral Doses of Gemifloxacin (320 Milligrams) versus Trovafloxacin (200 Milligrams) on Fecal Flora in Healthy Volunteers

Gloria Garcia-Calvo,1 Ana Molleja,1 Maria J. Giménez,2 Araceli Parra,1 Eva Nieto,1 Carmen Ponte,1 Lorenzo Aguilar,2 and Francisco Soriano1,*

Department of Medical Microbiology, Fundación Jiménez Díaz,1 and Medical Department, SmithKline Beecham Pharmaceuticals,2 Madrid, Spain

Received 15 June 2000/Returned for modification 25 August 2000/Accepted 22 November 2000

Gemifloxacin and trovafloxacin were administered to 12 volunteers in a randomized crossover trial with a 2-week washout period. Stool samples were collected predose and 1, 2, and 3 days postdose. Both quinolones reduced the number of organisms of the family Enterobacteriaceae and aerobic gram-positive organisms. Escherichia coli reduction was greater with gemifloxacin than with trovafloxacin, with postdose isolation of quinolone-resistant strains for which MICs of trovafloxacin were higher than those of gemifloxacin.

* Corresponding author. Mailing address: Department of Medical Microbiology, Fundación Jiménez Díaz, Avenida de Reyes Católicos 2, 28040 Madrid, Spain. Phone: 34-91-5447387. Fax: 34-91-5494764. E-mail: fsoriano{at}fjd.es.

Antimicrobial Agents and Chemotherapy, February 2001, p. 608-611, Vol. 45, No. 2
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.2.608-611.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.




Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»